

# Curcumin Vasorelaxation in Uterine Artery of Goat (*Capra hircus*) is Mediated by Differential Activation of Nitric Oxide, Prostaglandin I<sub>2</sub>, Soluble Guanylyl Cyclase, and Gap Junction Communication

Harithalakshmi Jandhyam, Subas Chandra Parija

Department of Pharmacology and Toxicology, Faculty of Veterinary Sciences, Orissa University of Agriculture and Technology, Bhubaneswar, Odisha, India

Submitted: 29-04-2019

Revised: 12-06-2019

Published: 28-11-2019


## ABSTRACT

**Background:** Curcumin is a principal active constituent of *Curcuma longa* and has potential therapeutic application in various disease states. In this study, we investigated the mechanism of vasorelaxatory effects of curcumin in middle uterine artery (MUA) of both pregnant (P) and nonpregnant (NP) *Capra hircus* (Ch). **Materials and Methods:** The middle uterine arterial rings (MUA) were mounted in an automatic organ bath attached to a PowerLab data acquisition system. We analyzed the effect of curcumin on signaling mediators of endothelium-derived hyperpolarizing factor: nitric oxide (NO), soluble guanylyl cyclase (sGC), prostaglandin I<sub>2</sub> (PGI<sub>2</sub>), and myoendothelial gap junctions (MEGJs). **Results:** The maximal vasorelaxation response to curcumin (1  $\mu$ M–100  $\mu$ M) induced in phenylephrine- precontracted endothelium intact and denuded MUA rings were 42.58%, 25.12% in NP and 55.49%, 12.66%, in P Ch. In the presence of 1H-(1,2,4) oxadiazolo (4,3,-a) quinoxalin-1-one, the maximal curcumin-induced vasorelaxation (CVR) was inhibited to 20.65%, and 15.81% in MUA of NP and P Ch. In the presence of N-nitro-L-arginine methyl, indomethacin and combination of both CVR were decreased to 20.49%, 12.47%, 12.82% in MUA ring of NP and to 40.60%, 52.55%, 46.53% in MUA ring of P Ch, respectively. The sensitivity of curcumin to MEGJ blockers carbenoxolone, 18 $\beta$ -glycyrrhetic acid in causing vasorelaxation was 33.18%, 22.61% in MUA rings of NP; and to 15.76%, 18.54% in P Ch. **Conclusion:** In P Ch, endothelium-dependent vasorelaxation to curcumin is augmented by two-fold as that of MUA of NP. Endothelial vasorelaxation in MUA of NP is mediated through the activation of cyclooxygenase-PGI<sub>2</sub>-cyclic adenosine monophosphate and endothelial NO synthase (eNOS)-sGC-cyclic guanosine monophosphate (cGMP) signaling with low activation of sGC and MEGJ. In contrast, vasorelaxation to curcumin is mediated through increased activity of sGC and MEGJ with major involvement of eNOS-NO-sGC-cGMP in MUA of P Ch. These studies have strong implications in the therapeutic targeting for hypertensive disorders.

**Key words:** Curcumin, hypertension, nitric oxide, uterine artery, vasorelaxation

## SUMMARY

- Curcumin-induced vasorelaxation in middle uterine artery of both nonpregnant and pregnant *Capra hircus*. Curcumin-induced vasorelaxation in the middle uterine artery of nonpregnant *Capra hircus* is endothelium-dependent through cyclooxygenase-prostaglandin I<sub>2</sub> and endothelial nitric oxide synthase-nitric oxide pathways with an additional participation of myoendothelial gap junction. Endothelial nitric oxide synthase-nitric oxide pathway and myoendothelial gap junction play a vital role in middle uterine artery of pregnant *Capra hircus*. Data suggest a novel role of curcumin in the treatment of hypertensive disorders such as preeclampsia.



**Abbreviations used:** cAMP: Cyclic adenosine monophosphate; cGMP: Cyclic guanosine monophosphate; Ch: *Capra hircus*; COX: Cyclooxygenase; CVR: Curcumin-induced vasorelaxation; EC: Endothelial cell; ED-: Endothelium denuded; ED+: Endothelium intact; EDHF: Endothelium-derived hyperpolarizing factor; eNOS: Endothelial Nitric oxide synthase; IC<sub>50</sub>: Half maximal inhibitory concentration; L-NAME: N-nitro-L-arginine methyl ester hydrochloride; MEGJ: Myoendothelial gap junctions; MUA: Middle uterine artery; NO: Nitric oxide; NP: Nonpregnant; ODO: 1H-(1,2,4) oxadiazolo (4,3,-a) quinoxalin-1-one; P: Pregnant; PGI<sub>2</sub>: Prostaglandin; PKA: Phosphokinase-A; PKG: Phosphokinase-G; pIC<sub>50</sub>-log (IC<sub>50</sub>); R<sub>max</sub>: Maximum relaxation; R<sub>Bmax</sub>: Maximum relaxation in the presence of blocker; sGC: Soluble guanylyl cyclase; VSMC: Vascular smooth muscle cell.

## Correspondence:

Prof. Subas Chandra Parija,  
Department of Pharmacology and Toxicology,  
Faculty of Veterinary Sciences, Orissa  
University of Agriculture and Technology,  
Bhubaneswar - 751 003, Odisha, India.  
E-mail: [profscparijauat4691@gmail.com](mailto:profscparijauat4691@gmail.com)  
DOI: 10.4103/pm.pm\_188\_19

## Access this article online

Website: [www.phcog.com](http://www.phcog.com)

## Quick Response Code:



This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: [reprints@medknow.com](mailto:reprints@medknow.com)

**Cite this article as:** Jandhyam H, Parija SC. Curcumin vasorelaxation in uterine artery of goat (*Capra hircus*) is mediated by differential activation of nitric oxide, prostaglandin I<sub>2</sub>, soluble guanylyl cyclase, and gap junction communication. *Phcog Mag* 2019;15:S495-501.

## INTRODUCTION

Nitric oxide (NO) once described as the “Miracle Molecule” won the molecule of the year award in 1992. Robert F. Furchgott and colleagues were honored with a Nobel Prize for their invention of “NO as a signaling molecule in the cardiovascular system” in 1998.<sup>[1]</sup> NO plays a critical role in the maintenance of vascular tone through relaxing vascular smooth muscle cells. Three isoforms of NOS are now known to exist, two of which are constitutive and one of which is inducible by immunological stimuli,<sup>[2]</sup> namely endothelial NO synthase (eNOS) in vascular endothelium, nNOS in neurons, and iNOS in response to immunological stimuli.<sup>[3]</sup> The most well-distinguished vasorelaxation mechanism of NO is the stimulation of soluble guanylyl cyclase (sGC) in smooth muscle cells. Activated sGC catalyzes the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). cGMP targets protein kinase G (PKG) in smooth muscle cells, activates the myosin light-chain phosphatase, which dephosphorylates smooth muscle myosin. This process results in loss of tonic contraction of the contractile apparatus which leads to vasorelaxation.<sup>[4]</sup>

Myoendothelial gap junctions (GJs) bridge endothelial cells (ECs) and smooth muscle cells. The hyperpolarization in smooth muscle cells is basically conducted from the ECs through myoendothelial GJs (MEGJs), since smooth muscle and ECs are coupled.<sup>[5]</sup> Connexins play specific roles in estradiol-17  $\beta$ -treatment-regulated uterine function and placental development during early gestation.<sup>[6]</sup> In rat and guinea-pig small arteries, rabbit iliac arteries pharmacological blockade of GJs blunts endothelium-derived hyperpolarizing factor (EDHF)-mediated responses.<sup>[7]</sup> Under hypertensive conditions GJ-mediated response possibly dysfunctional as in spontaneously hypertensive rats (SHR), the protein expressions of connexins in ECs of the mesenteric arteries were altered compared to those in Wistar-Kyoto rats.<sup>[8]</sup>

During normal pregnancy, there is an increase in the activity of eNOS, cyclooxygenase (COX) and increased production of NO, prostaglandin I<sub>2</sub> (PGI<sub>2</sub>), and EDHF. NO acts through the stimulation of the sGC that increases cGMP and PGI<sub>2</sub> increases cyclic adenosine monophosphate (cAMP) in smooth muscle respectively, which in turn decrease intracellular Ca<sup>2+</sup> and the myofilament sensitivity to Ca<sup>2+</sup>. On the other hand EDHF activates K<sup>+</sup> channels in vascular smooth muscle cell membrane and causes hyperpolarization that results vasorelaxation. This mechanism resulted in smooth muscle relaxation and decreased peripheral resistance and arterial pressure. Hypertension is the most common health disorder of pregnancy and is reported to complicate up to 10% of pregnancies and is associated with increased maternal and neonatal morbidity and mortality.<sup>[9]</sup> In preeclampsia, there is increased release of placental cytokines such as tumor necrosis factor-alpha and interleukin-1 that inhibit the production of endothelium-derived relaxing factors and thus decrease smooth muscle relaxation.

Curcumin ([1E,6E]-1,7-bis[4-hydroxy-3-methoxyphenyl]-1,6-heptadiene-3,5-dione) is an active principal constituent of turmeric, dried yellow powder obtained from the rhizomes of *Curcuma longa*. Curcumin has antioxidant, antibacterial, antifungal, antiviral, anti-inflammatory, antiproliferative, proapoptotic, and anti-atherosclerotic effects.<sup>[10]</sup> It has shown beneficial effects against cardiovascular diseases, neurodegenerative diseases, arthritis, allergy, inflammatory bowel disease, nephrotoxicity, AIDS, psoriasis, diabetes, multiple sclerosis, lung fibrosis, and as an alternative therapy for uterine leiomyoma.<sup>[11]</sup> Previous studies suggest that the pleiotropic effects of curcumin are reliant on its ability of interacting and regulation of multiple molecular targets.<sup>[12]</sup> These targets include inflammatory cytokines, transcription factors, growth factors, kinases, adhesion molecules, and apoptosis-related proteins.<sup>[13]</sup>

The role of EDH in vasorelaxation mechanism of curcumin is lacking in the uterine artery of any species. The study investigated the role of eNOS-NO-cGMP and COX-PGI<sub>2</sub> in relation to MEGJ in mediating endothelium-dependent hyperpolarization in middle uterine artery (MUA) of nonpregnant (NP) and pregnant (P) *Capra hircus* (Ch). Further, our study strongly supports that the administration of curcumin augments uterine blood flow (UBF) that can be helpful in maintenance of fetal health and diseases such as preeclampsia, a pregnancy complication characterized with high blood pressure.

## MATERIALS AND METHODS

### Ethical approval

This work was approved by Institutional Animal Ethical Committee (Registration No: 433/CPCSEA/CVS vide ID. No. 1586: (6)/CVS/dt. 03.05.2016 for conducting randomized *ex vivo* animal tissue experiments.

### Preparation of middle uterine artery

Both NP and P uteri with broad ligament intact along with uterine artery were obtained in an aerated ice-cold (4°C–6°C) modified Krebs–Henseleit Saline solution to the laboratory. Secondary branch of uterine artery supplied to the uterine horn carefully cleared of fascia and connective tissue was cut into segments of circular rings measuring 1.5–2 mm in length. The arterial rings were then mounted between two fine stainless-steel L-shaped hooks and kept under a resting tension of 1.5 g in a thermostatically controlled (37.0°C  $\pm$  0.5°C) automatic organ bath (Pan Lab) of 20 mL capacity bubbled with carbogen (95% O<sub>2</sub> + 5% CO<sub>2</sub>). Endothelium-denuded (ED–) rings were prepared by cotton swab method, i.e., endothelium removal was attained by gently passing a wet cotton thread 2–3 times in each direction through the lumen of the arterial ring.<sup>[14,15]</sup> The change in isometric tension was measured by a highly sensitive isometric force transducer (Model: MLT0201, AD Instruments Pty Ltd, Bella Vista, New South Wales, Australia) and analyzed using Lab Chart 7.1.3 software.

### Curcumin-induced concentration-related response in phenylephrine-precontracted endothelium intact/ endothelium-denuded middle uterine artery rings

Curcumin (1  $\mu$ M–100  $\mu$ M) was added to bath cumulatively with an increment of 1.0 log unit at 4 min interval to relax the sustained contraction induced by phenylephrine (PE) (10  $\mu$ M). Net tension (g) at each concentration of curcumin was recorded. The concentration-related response curves of curcumin were elicited and shift of the CRCs was compared between endothelium intact (ED+) and ED– groups. Maximum relaxation/maximum relaxation in presence of blocker ( $R_{max}/R_{Bmax}$ ), mean threshold concentration, and pIC<sub>50</sub>, were calculated for MUA rings for NP and P groups.

### Curcumin-induced vasorelaxation in the presence of 1H-(1,2,4) oxadiazolo (4,3,-a) quinoxalin-1-one or N<sub>w</sub>-nitro-L-arginine methyl ester hydrochloride or indomethacin or N<sub>w</sub>-nitro-L-arginine methyl ester hydrochloride and indomethacin or carbenoxolone or 18 $\beta$ -glycyrrhetic acid in phenylephrine-precontracted middle uterine artery rings

In order to examine curcumin (1  $\mu$ M–100  $\mu$ M)-induced vasorelaxation involving the endothelium-dependent mechanisms, the arterial rings

were preincubated with 10  $\mu$ M of 1H-(1,2,4) oxadiazolo (4,3-a) quinoxalin-1-one (ODQ) or  $N_{\omega}$ -Nitro-L-arginine methyl ester hydrochloride (L-NAME) or indomethacin or L-NAME and indomethacin for 15 min and carbenoxolone or 18 $\beta$ -glycyrrhetic acid for 30 min prior to PE precontraction. Curcumin was added with increment of 1.0 log unit in a cumulative manner into the bath at 4 min interval after attaining a plateau contraction induced by PE. The concentration-related response curves of curcumin were elicited and shift of the CRCs were compared with nontreated control.  $R_{max}/R_{Bmax}$  (maximal relaxation), mean threshold concentration and  $pIC_{50}$  (-log of concentration causing 50% inhibitory response), were calculated for MUA rings of NP and P *Ch*.

### Statistical analysis

The data were expressed as a percentage of relaxation at different concentration of curcumin in the absence or presence of pathways blockers and analyzed by the interactive nonlinear regression through the computer program Graph Pad Prism 5 (Graph Pad Prism Software, San Diego, CA, USA). Mean of  $R_{max}$ ,  $R_{Bmax}$ ,  $pIC_{50}$  was calculated for each set of concentration-related vasorelaxation curve and compared using unpaired Student's *t*-test with the help of Graph Pad Software Quick Calcs (San Diego, CA, U. S. A). *P* < 0.05 was considered statistically significant.

### Drugs and chemicals

Curcumin (Sigma, USA), 18 $\beta$ -Glycyrrhetic Acid (MP Biochemicals, India), NG-nitro-L-arginine methyl ester (L-NAME), ODQ (Cayman Chemical, USA), and carbenoxolone (Sigma, USA) were employed in this study. All the solutions were prepared fresh in triple-distilled water except for 18  $\beta$ GA, ODQ which were dissolved in dimethyl sulfoxide, and indomethacin, dissolved in ethanol. Curcumin was prepared in 0.5N NaOH and phosphate-buffered saline.

## RESULTS


### Effect of curcumin (1 pM–100 $\mu$ M) in phenylephrine (10 $\mu$ M)-precontracted middle uterine artery rings

Table 1 represents the percentage maximal vasorelaxation ( $R_{max}$ ) and  $pIC_{50}$  of curcumin in MUA of NP and P *Ch*. The representative raw traces show curcumin (1 pM–100  $\mu$ M)-induced vasorelaxation elicited in PE-precontracted ED+ and ED– MUA

rings of NP and P groups at Figure 1a and b, respectively. Curcumin (1 pM–100  $\mu$ M) inhibited PE-induced sustained contraction in both NP and P *Ch* in a concentration-dependent manner. Curcumin-induced vasorelaxation (CVR) curve ( $R_{max}$  42.58%  $\pm$  1.84%;  $pIC_{50}$  8.83  $\pm$  0.10) elicited in ED+ MUA rings of NP *Ch*, was shifted to right with significant (*P* < 0.001) decrease in  $R_{max}$  (25.12  $\pm$  1.16%) and nonsignificant decrease in  $pIC_{50}$  (8.53  $\pm$  0.14) in ED– rings of NP *Ch* [Figure 2a]. In MUA of P *Ch*, CVR curve ( $R_{max}$  55.49%  $\pm$  1.69%;  $pIC_{50}$  9.17  $\pm$  0.10) elicited in ED+ rings was shifted to right with significant (*P* < 0.001) decrease in  $R_{max}$  (12.66%  $\pm$  1.66%) and  $pIC_{50}$  (5.99  $\pm$  0.12) in ED– rings [Figure 2b].

### Effect of $N_{\omega}$ -nitro-L-arginine methyl ester hydrochloride or indomethacin or $N_{\omega}$ -nitro-L-arginine methyl and indomethacin on curcumin-induced vasorelaxation

L-NAME, eNOS inhibitor and indomethacin, a COX inhibitor, and both attenuated curcumin vasorelaxation in PE precontracted MUA rings [Table 1]. In MUA of NP *Ch*, CVR curve ( $R_{max}$  42.58%  $\pm$  1.84%;  $pIC_{50}$  8.83  $\pm$  0.10) was shifted right with significant (*P* < 0.001) decrease in  $R_{Bmax}$  (20.49%  $\pm$  1.02%) and



**Figure 1:** Representative raw trace showing effect of curcumin (1 pM–100  $\mu$ M) on Phenylephrine (10  $\mu$ M)-induced sustained contraction in the presence of endothelium (Endothelium intact) and in the absence of endothelium (Endothelium denuded) in middle uterine artery ring of (a) nonpregnant *Capra hircus* and (b) pregnant *Capra hircus*

**Table 1:** Maximum relaxation and - log half-maximal inhibitory concentration of curcumin in endothelium intact or in endothelium-denuded or in absence (maximum relaxation) or in presence (maximum relaxation in presence of blocker) of  $N_{\omega}$ -Nitro-L-arginine methyl ester hydrochloride or indomethacin or  $N_{\omega}$ -Nitro-L-arginine methyl ester hydrochloride and indomethacin or 1H-[1,2,4] oxadiazolo[4,3,-a] quinoxalin-1-one or carbenoxolone or 18 $\beta$ -glycyrrhetic acid in phenylephrine-precontracted middle uterine artery rings of nonpregnant and pregnant *Capra hircus*

Treatment	n value		$R_{max}/R_{Bmax}$ (%)		$pIC_{50}$	
	NP	P	NP	P	NP	P
Control (ED+)	11	12	42.58 $\pm$ 1.84	55.49 $\pm$ 1.69	8.83 $\pm$ 0.10	9.17 $\pm$ 0.10
ED–	6	6	25.12 $\pm$ 1.16 <sup>a</sup>	12.66 $\pm$ 1.66 <sup>a</sup>	8.53 $\pm$ 0.14	5.99 $\pm$ 0.12 <sup>a</sup>
L-NAME	6	6	20.49 $\pm$ 1.02 <sup>a</sup>	40.60 $\pm$ 1.18 <sup>a</sup>	9.05 $\pm$ 0.17	11.39 $\pm$ 0.31 <sup>a</sup>
Indomethacin	6	6	12.47 $\pm$ 1.07 <sup>a</sup>	52.55 $\pm$ 1.62	8.01 $\pm$ 0.13 <sup>b</sup>	10.13 $\pm$ 0.15 <sup>a</sup>
L-NAME + Indo	6	6	12.82 $\pm$ 0.32 <sup>a</sup>	46.53 $\pm$ 1.75 <sup>b</sup>	7.28 $\pm$ 0.09 <sup>a</sup>	8.89 $\pm$ 0.14
ODQ	6	6	20.65 $\pm$ 0.34 <sup>a</sup>	15.81 $\pm$ 0.99 <sup>a</sup>	6.79 $\pm$ 0.12 <sup>a</sup>	5.97 $\pm$ 0.09 <sup>a</sup>
Carbenoxolone	6	6	33.18 $\pm$ 0.96 <sup>a</sup>	15.76 $\pm$ 0.92 <sup>a</sup>	6.94 $\pm$ 0.13 <sup>a</sup>	6.74 $\pm$ 0.16 <sup>a</sup>
18 $\beta$ GA	6	6	22.61 $\pm$ 0.24 <sup>a</sup>	18.54 $\pm$ 0.5 <sup>a</sup>	7.67 $\pm$ 0.15 <sup>a</sup>	8.98 $\pm$ 6.74


<sup>a</sup>*P* < 0.001; <sup>b</sup>*P* < 0.05 represents the level of significance between the rows within each column. The values are expressed as mean  $\pm$  SEM. MUA: Middle uterine artery; n value: Total number of MUA rings used in the control or treatment groups;  $R_{max}$ : Maximum relaxation;  $R_{Bmax}$ : Maximum relaxation in presence of blocker;  $IC_{50}$ : Half maximal inhibitory concentration;  $pIC_{50}$ : -log ( $IC_{50}$ ); SEM: Standard error of mean; L-NAME:  $N_{\omega}$ -Nitro-L-arginine methyl ester hydrochloride; ODQ: 1H-[1,2,4] oxadiazolo[4,3,-a] quinoxalin-1-one; 18 $\beta$ GA: 18 $\beta$ -Glycyrrhetic acid; NP: Nonpregnant; P: Pregnant; Indo: Indomethacin; ED+: Endothelium intact; ED–: Endothelium denuded

nonsignificant increase in  $pIC_{50}$  ( $9.05 \pm 0.17$ ) in presence of L-NAME, with significant ( $P < 0.001$ ) decrease in  $R_{Bmax}$  ( $12.47\% \pm 1.07\%$ ) and significant ( $P < 0.05$ ) decrease in  $pIC_{50}$  ( $8.01 \pm 0.13$ ) in the presence of indomethacin. In the presence of both L-NAME and indomethacin, the CVR curve was also shifted to right with significant ( $P < 0.001$ ) decrease in  $R_{Bmax}$  ( $12.82\% \pm 0.32\%$ ) and  $pIC_{50}$  ( $7.28 \pm 0.09$ ) [Figure 3a]. In MUA of P *Ch*, CVR curve ( $R_{max}$   $55.49\% \pm 1.69\%$ ;  $pIC_{50}$   $9.17 \pm 0.10$ ) was shifted to right with significant ( $P < 0.001$ ) decrease in  $R_{Bmax}$  ( $40.60\% \pm 1.18\%$ ) and increase in  $pIC_{50}$  ( $11.39 \pm 0.31$ ) in the presence of L-NAME, with non-significant decrease in  $R_{Bmax}$  ( $52.55 \pm 1.62\%$ ) and significant ( $P < 0.001$ ) increase in  $pIC_{50}$  ( $10.13 \pm 0.15$ ) in the presence


of indomethacin. In the presence of L-NAME and indomethacin, the CVR curve was shifted to right with significant ( $P < 0.05$ ) decrease in  $R_{Bmax}$  ( $46.53\% \pm 1.75\%$ ) and nonsignificant decrease in  $pIC_{50}$  ( $8.89 \pm 0.14$ ) [Figure 3b].

### Effect of 1H-(1,2,4) oxadiazolo (4,3-a) quinoxalin-1-one on curcumin-induced vasorelaxation


In MUA of NP *Ch*, in the presence of ODQ (sGC inhibitor,  $10 \mu M$ ), CVR curve showed rightward shift with significant ( $P < 0.001$ ) decrease



**Figure 2:** Curcumin ( $1 \mu M$ – $100 \mu M$ )-induced concentration-response curve elicited in the presence of endothelium (endothelium intact) and in the absence of endothelium (endothelium-denuded) in middle uterine artery ring of (a) nonpregnant *Capra hircus* and (b) pregnant *Capra hircus*



**Figure 3:** Curcumin ( $1 \mu M$ – $100 \mu M$ )-induced concentration-response curve elicited in absence (control) or in presence of  $N_{\omega}$ -nitro-L-arginine methyl ester hydrochloride ( $10 \mu M$ ) or indomethacin (Indo,  $10 \mu M$ ) or  $N_{\omega}$ -Nitro-L-arginine methyl ester hydrochloride and indomethacin ( $N_{\omega}$ -Nitro-L-arginine methyl + Indo,  $10 \mu M$ ) in middle uterine artery ring of (a) nonpregnant *Capra hircus* and (b) pregnant *Capra hircus*



**Figure 4:** Curcumin ( $1 \mu M$ – $100 \mu M$ )-induced concentration-response curve elicited in absence (control) or in presence of 1H-(1,2,4) oxadiazolo (4,3-a) quinoxalin-1-one ( $10 \mu M$ ) in middle uterine artery ring of (a) nonpregnant *Capra hircus* and (b) pregnant *Capra hircus*

in  $R_{\text{Bmax}}$  ( $20.65\% \pm 0.34\%$ ) and  $\text{pIC}_{50}$  ( $6.79 \pm 0.12$ ) as compared to NP *Ch* control [Table 1 and Figure 4a]. In the presence of ODQ, CVR curve ( $R_{\text{max}}$   $55.49\% \pm 1.69\%$ ;  $\text{pIC}_{50}$   $9.17 \pm 0.10$ ) was shifted to right with significant ( $P < 0.001$ ) decrease in  $R_{\text{Bmax}}$  ( $15.81\% \pm 0.99\%$ ) and  $\text{pIC}_{50}$  ( $5.97 \pm 0.09$ ) in MUA of P *Ch* [Table 1 and Figure 4b].

### Effect of gap junction uncouplers carbenoxolone/18 $\beta$ -glycyrrhetic acid

GJ uncouplers or connexin inhibitors such as carbenoxolone and 18 $\beta$ -glycyrrhetic acid altered CVR significantly in MUA rings of both NP and P *Ch* [Table 1]. In the presence of carbenoxolone and 18 $\beta$ -glycyrrhetic acid, the CVR curve was inhibited with significant ( $P < 0.001$ ) decrease in  $R_{\text{Bmax}}$  and  $\text{pIC}_{50}$  ( $33.18\% \pm 0.96\%$  and  $6.74 \pm 0.16$ ) and ( $22.61\% \pm 0.24\%$  and  $7.67 \pm 0.15$ ), respectively, in MUA of NP *Ch* [Figure 5a]. In MUA of P *Ch*, carbenoxolone inhibited the vasorelaxation to curcumin with rightward shift of CVR curve with significant ( $P < 0.001$ ) decrease in  $R_{\text{Bmax}}$  and  $\text{pIC}_{50}$  ( $15.76\% \pm 0.92\%$ ,  $6.94 \pm 0.13$ ). 18 $\beta$ -glycyrrhetic acid caused CVR curve significant ( $P < 0.001$ ) decrease in  $R_{\text{Bmax}}$  ( $18.54\% \pm 0.50\%$ ) and nonsignificant increase in  $\text{pIC}_{50}$  ( $8.98 \pm 6.74$ ) [Figure 5b].

## DISCUSSION


It has been well accepted that the mechanisms of vasorelaxation to curcumin varies with the location of blood vessels and species of animals.<sup>[16-20]</sup> Due to lack of literature it is not known whether curcumin has potential to cause vasorelaxation in uterine artery, if it causes what are the underlying possible signalling mechanisms involved in mediating vasorelaxation. To answer these questions, the vasorelaxation effect of curcumin was elicited in MUA of both NP and P goat in the presence of endothelial vasorelaxation signaling pathways inhibitors. The most important findings are (i) The maximal vasorelaxation obtained from CVR curve elicited in PE-precontracted ED + MUA rings was greater in P *Ch* than that of NP *Ch* [Table 1] suggesting a greater vasorelaxation action of curcumin in MUA of P *Ch*. (ii) Endothelium removal attenuated the maximal CVR in MUA of P more than NP *Ch*. This finding clearly demonstrate that endothelium-dependent vasorelaxation to curcumin is greatly augmented in MUA of P than NP *Ch*. (iii) L-NAME, indomethacin, L-NAME + Indomethacin decreased the maximal CVR in MUA ring of NP as compared to MUA ring of P *Ch* [Table 1]. These observations suggest that curcumin activates COX predominantly and eNOS moderately in NP *Ch*. In contrast, curcumin activates only eNOS moderately but not COX raising the possibility of involvement of other endothelium-dependent mechanisms in MUA of P *Ch*. (iv) In the presence of ODQ, the maximal CVR was inhibited in MUA of NP and P *Ch* indicating that increased blocking effect of sGC by curcumin

in MUA of P *Ch*, (v) carbenoxolone, 18 $\beta$ -glycyrrhetic acid reduced the maximal CVR in MUA rings of NP and in P *Ch* demonstrating an increased blocking effect of MEGJ uncouplers in MUA of P *Ch*.

Vasodilation effect of curcumin has been reported in rat aorta,<sup>[16]</sup> porcine coronary arteries,<sup>[17]</sup> rabbit basilar arteries,<sup>[18]</sup> goat ruminal artery,<sup>[19]</sup> and rat mesenteric arteries.<sup>[20]</sup> Hexahydrocurcumin (HHC) relaxed the ED+ rat aortic rings precontracted with PE and KCl in a concentration-dependent manner and no effect observed in the absence of endothelium suggesting that vasorelaxation to HHC is endothelium-dependent.<sup>[21]</sup> The administration of dietary curcumin for 1 month remarkably restored the impaired cerebrovascular endothelium-dependent vasorelaxation in aging SD rats.<sup>[22]</sup> In the same study, it was shown that curcumin promoted eNOS and AMPK phosphorylation, UCP<sub>2</sub> upregulation and reduced ROS production in the cultured ECs prepared from the cerebral arteries of aging SD rats further demonstrated that curcumin interacts with several targets of vasorelaxation pathways.

Curcumin-induced maximal vasorelaxation in ED+ MUA rings of NP and P *Ch* was attenuated in that of ED- rings. Hence, the maximal percentage vasorelaxation to curcumin is endothelium-dependent in uterine artery of NP and P *Ch*. To rule out the differential activation of NO, PGI<sub>2</sub>, or EDHF by curcumin in MUA rings of NP or P *Ch*, CVR curve was elicited in the absence or presence of eNOS, COX inhibitors. L-NAME, indomethacin, and L-NAME+Indomethacin, significantly decreased the maximal CVR in MUA ring of NP *Ch*. The percent abolition of CVR following blockade of eNOS is almost equal to the CVR abolished due to removal of endothelium. In contrast, the percentage abolition of CVR following blockade of COX or both eNOS and COX is greater than the CVR due to endothelium. These findings clearly demonstrated that curcumin vasorelaxation is mediated in part through the activation of eNOS-NO signaling. Curcumin activates eNOS that increases the turnover of NO in the endothelium of MUA which is diffusing to the vascular smooth muscle cells where it is interacting with sGC to activate cGMP and cause vasorelaxation. In order to examine the involvement of sGC, CVR curve was elicited in the presence of sGC blocker ODQ. ODQ almost inhibited the maximal CVR, and this is almost identical to either the percentage vasorelaxation abolished with removal of endothelium or blockade of eNOS. Hence, one of the endothelial mechanisms of vasorelaxation to curcumin is mediated through the activation of eNOS-NO-sGC-cGMP signaling pathways.<sup>[17]</sup>

In MUA of P *Ch*, L-NAME, indomethacin both L-NAME and indomethacin inhibited the maximal CVR in MUA ring of P *Ch* indicating that CVR is mediated by activation eNOS in part but not COX. While comparing the attenuated percentage of vasorelaxation to curcumin in endothelium-denuded rings (42%) with that of



**Figure 5:** Curcumin (1  $\mu\text{M}$ –100  $\mu\text{M}$ )-induced concentration-response curve elicited in the absence (control) or presence of carbenoxolone (Carbenox, 10  $\mu\text{M}$ ) or 18 $\beta$ -Glycyrrhetic acid (18 $\beta$ -GA, 10  $\mu\text{M}$ ), in middle uterine artery ring of (a) nonpregnant *Capra hircus* and (b) pregnant *Capra hircus*

abolished CVR in the presence of L-NAME or/and indomethacin, it can be stated that a greater proportion of curcumin vasorelaxation is mediated by the activation of endothelium-dependent eNOS-NO mechanisms. The endothelium-dependent mechanism has been reported in coronary artery of dogs and humans<sup>[23]</sup> and rat aorta.<sup>[24]</sup> L-NAME insensitive mechanism is observed in cerebral vasculature of mice<sup>[25]</sup> and the endothelium-dependent, eNOS-independent inhibition is caused by NO produced by cytochrome P450 reductase in the endothelium of the SHR aorta.<sup>[26]</sup> In addition, eNOS, EDHF, and COX contribute to endothelium-dependent relaxation in the rat hepatic artery.<sup>[27]</sup> In PGF<sub>2α</sub>-precontracted porcine coronary arterial rings, curcumin ( $10^{-11}$ – $10^{-5}$  mol/l) vasorelaxation significantly reduced by removal of endothelium, and by the addition of L-NMMA, but not by indomethacin suggesting that curcumin might activate NO and cGMP but not COX-PGI<sub>2</sub>.<sup>[17]</sup> Our observation showed that about 43% of vasorelaxation to curcumin is endothelium-dependent. In contrast, only 15% of the endothelium-dependent vasorelaxation is mediated by eNOS-NO pathways. Hence, it is quite possible that a major component endothelial vasorelaxation to curcumin could be mediated by mechanism not involving eNOS and COX. Considering that the direct amplification of sGC activity in vascular smooth muscle cell (VSMC) by curcumin could be another additional mechanism to cause vasorelaxation through cGMP pathways as the CVR was attenuated in the presence of ODQ, a selective blocker of sGC. We observed that the maximal CVR was attenuated to 16% by ODQ indicating that the sensitivity of sGC to ODQ is greatly increased. The possible explanation for the increased sensitivity of sGC in the endothelium-dependent vasorelaxation to curcumin could be arising due to increase in the affinity or expression of sGC for binding of NO which in turn augmented the turnover of cGMP in the VSMC of MUA of P *Ch*. In goat ruminal artery, ODQ (10 μM) potentially blocked curcumin (10 nM–100 μM)-induced vasorelaxation in dose-dependent manner in 5-HT and NA-induced contraction suggesting curcumin at least in part, act through direct activation of sGC-mediated cGMP pathway followed by opening of K<sup>+</sup> ion channel.<sup>[19]</sup> In accordance to the findings made in goat ruminal artery, it could be convincing to explain that curcumin probably increases the sensitivity of sGC for NO binding thereby augmenting turnover of cGMP in MUA of P *Ch*. In conclusion, the endothelium-dependent and eNOS independent vasorelaxation to curcumin observed in isolated MUA of both NP and P *Ch* is mediated almost exclusively by the activation of sGC-cGMP pathways.

In vascular relaxation, PGI<sub>2</sub> and its analogs have been associated with concomitant hyperpolarization of the smooth muscle cells via opening of K<sup>+</sup>-channels. Basing on the type, location, and species the opening of various populations of K<sup>+</sup>-channels are involved.<sup>[28]</sup> In numerous vascular bed, PGI<sub>2</sub> has been considered as an endothelium-derived hyperpolarizing substance.<sup>[29]</sup> The blockade of COX reduced the endothelial production of PGI<sub>2</sub> leading to attenuation of vasorelaxation to curcumin in MUA. The blockade of COX or eNOS and COX reduced the CVR by 30% and by <5% in MUA of NP and P *Ch* indicating that COX-PGI<sub>2</sub> signaling is predominantly and minimally activated by curcumin in MUA of NP and P *Ch*, respectively. In MUA of NP *Ch*, the percentage of vasorelaxation abolished by COX blockade exceeds the percentage of vasorelaxation due to removal of endothelium. Hence, it is convincing to explain that curcumin activates PGI<sub>2</sub> in the endothelium that is associated with the hyperpolarization in the smooth muscle cells via opening of K<sup>+</sup>-channels as reported in several other vascular bed.<sup>[28,29]</sup> In goat MUA, curcumin showed differential sensitivity to different K<sup>+</sup> channels, caused direct hyperpolarization and vasorelaxation of VSMCs by opening of K<sub>Ca</sub>, K<sub>ATP</sub>, K<sub>ir</sub>, K<sub>v</sub> channels in NP *Ch* and K<sub>Ca</sub>, and K<sub>ir</sub> channels in P *Ch*.<sup>[30]</sup> In rat superior mesenteric artery, it has been reported that curcumin-mediated vasorelaxation involves indomethacin-sensitive COX-PGI<sub>2</sub> but not L-NAME and ODQ sensitive pathways. Similarly,

curcumin caused vasorelaxation in superior mesenteric arterial rings through an endothelium-dependent pathway involving prostanoids and also through an endothelium independent pathway, opening of K<sup>+</sup>-channels, blockade of Ca<sup>2+</sup>-influx, and intracellular Ca<sup>2+</sup>.<sup>[20]</sup> In MUA of NP goat, one of the predominant endothelium-dependent mechanism for CVR involves prostanoids (COX-PGI<sub>2</sub>-cAMP signaling pathways) that could be associated with hyperpolarization in smooth muscle cells through opening of opening of K<sup>+</sup>-channels, blockade of Ca<sup>2+</sup>-influx, and intracellular Ca<sup>2+</sup>.

GJs are compactly packed clusters of intercellular channels between endothelial- ECs and endothelial-VSM cells that connects cells electrically and metabolically.<sup>[31]</sup> The GJ directly couples the cytoplasm of adjacent cells to facilitate passage of ions, signaling molecules, and second messengers.<sup>[32]</sup> During pregnancy, the EC adaptation engages in significant role in the modulation of vascular resistance and UBF through increase in the PGI<sub>2</sub> and NO.<sup>[33]</sup> MEGJ plays a critical role in the elevations of these endothelial vasodilators through cell-cell signaling process by enhancement of cell connectivity.<sup>[34]</sup> The functional role of MEGJ in CVR in MUA of NP and P *Ch* is not elucidated. In consideration of potential endothelium-dependent vasorelaxation to curcumin in MUA of NP *Ch* and its further augmentation in that of P *Ch*, it is expected that MEGJ could be playing role in vasorelaxation mechanism of curcumin. In order to examine this, CVR curve was elicited in presence of two GJ uncouplers namely, carbenoxolone, and 18β-glycyrrhetic acid. Both the GJ uncouplers reduced the maximal CVR in MUA rings of NP and P *Ch*. This clearly showed that in MUA the sensitivity to these GJ uncouplers is increased from NP to P *Ch*. Further, the attenuation of percentage maximal CVR in absence of endothelium is almost close to the inhibition by these MEGJ uncouplers indicating that endothelium-dependent vasorelaxation to curcumin could be involving the MEGJ. Reports showed that curcumin-induced increase efflux of GSH in astrocyte cells of SD rat attenuated by GJ uncoupler carbenoxolone.<sup>[35]</sup> Dietary feeding with curcumin and tetrahydrocurcumin reduced the level of connexin-43 (molecule of GJs), in cancer cells of experimental colon carcinoma in mice.<sup>[36]</sup> These findings clearly suggest that the MEGJ plays functional role in the transportation of small signaling molecules and ions in subserving curcumin-mediated vasorelaxation in ED+ MUA of NP and this is greatly increased in P *Ch*. It is most likely that curcumin might be activating MEGJs in ED+ uterine vascular tissues that increase entry of Ca<sup>2+</sup> from VSMC to endothelium to activate eNOS and COX as reported by Stridh *et al.*,<sup>[35]</sup> in part or facilitating the transportation of PGI<sub>2</sub> to VSMC to cause hyperpolarization. In several vascular bed-like goat superior mesenteric artery.<sup>[37]</sup> GJ has been reported as one of the EDHFs. The activation of GJ communication in MUA observed in our present findings clearly indicates that EDHFs could be one of the targets for vasorelaxation to curcumin.

## CONCLUSION

These studies have provided ample evidence that curcumin caused a differential vasorelaxation in MUA of NP and P *Ch*. Endothelium-dependent vasorelaxation mechanisms of curcumin are greatly increased from nonpregnancy to pregnancy which may be arising from vascular remodeling leading to endothelial adaptation. In MUA of NP and P *Ch*, increase in the sensitivity of eNOS in the ECs, sGC in the VSMC and GJ communications by curcumin clearly depicts the involvement of eNO-sGC-cGMP signaling mechanisms in vasorelaxation. Apart from these mechanisms, PGI<sub>2</sub>-cAMP signaling pathway is potential mechanism in the vasorelaxation to curcumin in NP *Ch*. These studies indicate strong prospects of

curcumin in the therapeutic management for hypertensive disorders in pregnancy.

## Acknowledgements

We would like to thank Orissa University of Agriculture and Technology, Odisha, India, for providing the infrastructure facility to carry out this study.

## Financial support and sponsorship

The authors are grateful to the UGC, GOI, for providing student fellowship grant (NFO-2015-17-OBC-AND-33897) during the research work of one of the authors (Harithalakshmi Jandhyam).

## Conflicts of interest

There are no conflicts of interest.

## REFERENCES

1. Kang KT. Endothelium-derived relaxing factors of small resistance arteries in hypertension. *Toxicol Res* 2014;30:141-8.
2. Knowles RG, Moncada S. Nitric oxide synthases in mammals. *Biochem J* 1994;298 (Pt 2):249-58.
3. Moncada S, Higgs A, Furchgott R. International union of pharmacology nomenclature in nitric oxide research. *Pharmacol Rev* 1997;49:137-42.
4. Yamamoto Y, Fukuta H, Nakahira Y, Suzuki H. Blockade by 18beta-glycyrrhetic acid of intercellular electrical coupling in guinea-pig arterioles. *J Physiol* 1998;511 (Pt 2):501-8.
5. Dudzinski DM, Igarashi J, Greif D, Michel T. The regulation and pharmacology of endothelial nitric oxide synthase. *Annu Rev Pharmacol Toxicol* 2006;46:235-76.
6. Johnson ML, Redmer DA, Reynolds LP, Grazul-Bilska AT. Gap junctional connexin messenger RNA expression in the ovine uterus and placenta: Effects of estradiol-17β-treatment, early pregnancy stages, and embryo origin. *Domest Anim Endocrinol* 2017;58:104-12.
7. Edwards G, Félétou M, Gardener MJ, Thollon C, Vanhoutte PM, Weston AH. Role of gap junctions in the responses to EDHF in rat and guinea-pig small arteries. *Br J Pharmacol* 1999;128:1788-94.
8. Kansui Y, Garland CJ, Dora KA. Enhanced spontaneous  $Ca^{2+}$  events in endothelial cells reflect signalling through myoendothelial gap junctions in pressurized mesenteric arteries. *Cell Calcium* 2008;44:135-46.
9. Antza C, Cifkova R, Kotsis V. Hypertensive complications of pregnancy: A clinical overview. *Metabolism* 2018;86:102-11.
10. Zhou H, Beevers CS, Huang S. The targets of curcumin. *Curr Drug Targets* 2011;12:332-47.
11. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. *Int J Biochem Cell Biol* 2009;41:40-59.
12. Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, Priyadarsini IK, et al. Multitargeting by curcumin as revealed by molecular interaction studies. *Nat Prod Rep* 2011;28:1937-55.
13. Tsuiji K, Takeda T, Li B, Wakabayashi A, Kondo A, Kimura T, et al. Inhibitory effect of curcumin on uterine leiomyoma cell proliferation. *Gynecol Endocrinol* 2011;27:512-7.
14. Rosolowsky M, Pfister SL, Buja LM, Clubb FJ Jr., Campbell WB. Method of removal of aortic endothelium affects arachidonic acid metabolism and vascular reactivity. *Eur J Pharmacol* 1991;193:293-300.
15. Singh TU, Kathirvel K, Choudhury S, Garg SK, Mishra SK. Eicosapentaenoic acid-induced endothelium-dependent and -independent relaxation of sheep pulmonary artery. *Eur J Pharmacol* 2010;636:108-13.
16. Sasaki Y, Goto H, Tohda C, Hatanaka F, Shibahara N, Shimada Y, et al. Effects of curcuma drugs on vasomotion in isolated rat aorta. *Biol Pharm Bull* 2003;26:1135-43.
17. Xu PH, Long Y, Dai F, Liu ZL. The relaxant effect of curcumin on porcine coronary arterial ring segments. *Vascul Pharmacol* 2007;47:25-30.
18. Ahn CM, Park BG, Woo HB, Ham J, Shin WS, Lee S. Synthesis of sulfonyl curcumin mimics exerting a vasodilatation effect on the basilar artery of rabbits. *Bioorg Med Chem Lett* 2009;19:1481-3.
19. Dash JR, Parija SC. Spasmodic effect of curcumin on goat ruminal artery is endothelium independent and by activation of sGC. *Res Vet Sci* 2013;95:588-93.
20. Zhang H, Liu H, Chen Y, Zhang Y. The curcumin-induced vasorelaxation in rat superior mesenteric arteries. *Ann Vasc Surg* 2018;48:233-40.
21. Moohammadaree A, Changtam C, Wicha P, Saksamrarn A, Tocharus J, Tocharus C. Mechanisms of vasorelaxation induced by hexahydrocurcuminin isolated rat thoracic aorta. *Phytother Res* 2015;29:1806-13.
22. Pu Y, Zhang H, Wang P, Zhao Y, Li Q, Wei X, et al. Dietary curcumin ameliorates aging-related cerebrovascular dysfunction through the AMPK/uncoupling protein 2 pathway. *Cell Physiol Biochem* 2013;32:1167-77.
23. Thorin E, Parent R, Ming Z, Lavallée M. Contribution of endogenous endothelin to large epicardial coronary artery tone in dogs and humans. *Am J Physiol* 1999;277:H524-32.
24. Aloysius UI, Achike FI, Mustafa MR. Mechanisms underlining gender differences in phenylephrine contraction of normoglycaemic and short-term streptozotocin-induced diabetic WKY rat aorta. *Vascul Pharmacol* 2012;57:81-90.
25. Santhanam AV, d'Uscio LV, He T, Das P, Younkin SG, Katusic ZS. Uncoupling of endothelial nitric oxide synthase in cerebral vasculature of tg2576 mice. *J Neurochem* 2015;134:1129-38.
26. Zhao Y, Vanhoutte PM, Leung SW. Endothelial nitric oxide synthase-independent release of nitric oxide in the aorta of the spontaneously hypertensive rat. *J Pharmacol Exp Ther* 2013;344:15-22.
27. Zygmunt PM, Plane F, Paulsson M, Garland CJ, Högestätt ED. Interactions between endothelium-derived relaxing factors in the rat hepatic artery: Focus on regulation of EDHF. *Br J Pharmacol* 1998;124:992-1000.
28. Félétou M, Vanhoutte PM. Endothelium-dependent hyperpolarizations: Past beliefs and present facts. *Ann Med* 2007;39:495-516.
29. Parkington HC, Coleman HA, Tare M. Prostacyclin and endothelium-dependent hyperpolarization. *Pharmacol Res* 2004;49:509-14.
30. Jandhyam HL, Parija SC. Curcumin and nanocurcumin differentially activate  $K^+$  channels in uterine artery of non-pregnant and pregnant *Capra hircus*. *Ann Phytomed* 2018;7:165-72.
31. Welsh DG, Segal SS. Endothelial and smooth muscle cell conduction in arterioles controlling blood flow. *Am J Physiol* 1998;274:H178-86.
32. Goodenough DA, Paul DL. Gap junctions. *Cold Spring Harb Perspect Biol* 2009;1:a002576.
33. Bird IM, Sullivan JA, Di T, Cale JM, Zhang L, Zheng J, et al. Pregnancy-dependent changes in cell signaling underlie changes in differential control of vasodilator production in uterine artery endothelial cells. *Endocrinology* 2000;141:1107-17.
34. Xia X, Batra N, Shi Q, Bonewald LF, Sprague E, Jiang JX. Prostaglandin promotion of osteocyte gap junction function through transcriptional regulation of connexin 43 by glycogen synthase kinase 3/β-catenin signaling. *Mol Cell Biol* 2010;30:206-19.
35. Stridh MH, Correa F, Nodin C, Weber SG, Blomstrand F, Nilsson M, et al. Enhanced glutathione efflux from astrocytes in culture by low extracellular  $Ca^{2+}$  and curcumin. *Neurochem Res* 2010;35:1231-8.
36. Lai CS, Wu JC, Yu SF, Badmaev V, Nagabhusanam K, Ho CT, et al. Tetrahydrocurcumin is more effective than curcumin in preventing azoxymethane-induced colon carcinogenesis. *Mol Nutr Food Res* 2011;55:1819-28.
37. Mohanty I, Parija SC, Suklabaidya S, Rattan S. Acidosis potentiates endothelium-dependent vasorelaxation and gap junction communication in the superior mesenteric artery. *Eur J Pharmacol* 2018;827:22-31.